



## **Sinclair IS Pharma plc**

### **Disposal of Fazol G**

LONDON—March 18, 2013 –Sinclair IS Pharma plc (AIM: SPH.L), (“Sinclair IS”) the international specialty pharmaceutical company, announces the disposal of Fazol G for a cash consideration of €1.15 million to Laboratoires Majorelle a French company specializing in the therapy area of gynaecology. Fazol G is used in the treatment of fungal infections and forms part of the Fazol brand family. Fazol G generated revenues of £0.4 million in the last full financial year to 30<sup>th</sup> June 2012, 15% of overall revenues of the Fazol brand.

The disposal is in line with the Board’s strategy that planned non-core product disposals would finance a significant part of the €1.7 million redundancy and outplacement costs that arise on the closure of the French factory. Sinclair IS has now covered all these costs from the proceeds of non-core product disposals in the current financial year.

#### **Ends**

#### **For further information please contact:**

##### **Sinclair IS Pharma plc**

Chris Spooner  
Alan Olby  
Robert Taylor

**Tel: +44 (0) 20 7467 6920**

##### **Peel Hunt LLP**

James Steel  
Vijay Barathan

**Tel: +44 (0) 20 7418 8900**

#### **Notes to Editors:**

##### **About Sinclair IS Pharma plc –[www.sinclairispharma.com](http://www.sinclairispharma.com)**

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology; in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.